ABSTRACT
BACKGROUND Scientific evidence for digital health applications (apps) which claim to help in the prevention and management of Type 2 diabetes (T2D) is limited.
OBJECTIVES We aimed to evaluate the quality of currently available health apps for prevention of T2D amongst Asian Indians.
METHODS Using the keywords, ‘diabetes prevention’, ‘healthy lifestyle’ and ‘fitness’, a total of 1486 apps available in India via Google Play were assessed for eligibility by two independent reviewers. After initial screening using specific inclusion and exclusion criteria, 50 apps underwent a pre-specified rating based on user reviews, number of downloads and app size. Sixteen apps that scored ≥ 9 were shortlisted for further review using the Mobile App Rating Scale (MARS). MARS contains 2 main categories: Category I (Application Quality) and Category II (Application Subjective Quality). The mean MARS scores were used to identify the top ranked apps.
RESULTS The mean score for Category I of MARS rating was highest for ‘Google Fit: Health and Activity Tracking’ (4.55/5). This was followed by ‘Healthifyme - Diet Plan, Health and Weight Loss’ (4.45/5). For Category II of MARS, ‘Diabetes M’, ‘Google Fit: Health and Activity Tracking’ and Calorie Counter- My fitness pal’, ‘Healthifyme - Diet plan, Health and Weight Loss’ all scored equally well. On comparing the advantages and disadvantages of each of these applications, ‘Google Fit: Health and Activity Tracking’ and ‘Healthifyme - Diet plan, Health and Weight Loss’ again ranked the best.
CONCLUSIONS Our review identifies two commercially available apps ‘Google Fit: Health and Activity Tracking’ and ‘Healthifyme - Diet plan, Health and Weight Loss’ as being user friendly and good quality. Although encouraging, further research is needed to evaluate the efficacy of these apps for prevention of diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The project has been registered with Clinical Trials Registry of India (CTRI) - CTRI/2020/03/024327
Funding Statement
Funding: The research was supported by the UK National Institute for Health Research (NIHR) Official Development Assistance (ODA, award 16/136/68). The views expressed are those of the author(s) and not necessarily those of the NIHR. Acknowledgments: At Imperial College London, the infrastructure support was provided by the NIHR Imperial Biomedical Research Centre and the NIHR Imperial Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Disclosures: N.O has received honoraria for speaking and advisory board participation from Abbott Diabetes, Dexcom, Medtronic Diabetes, and Roche Diabetes. V.M has received research or educational grants or honoraria for speaking engagements or serving on advisory boards from Novo Nordisk, Servier, MSD, Novartis, Eli Lilly, M/s. USV, Lifescan J & J, Sanofi Aventis, Merck, Astra Zeneca, Boehringer Ingelheim, Abbott and from several Indian pharmaceutical companies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Madras Diabetes Research Foundation - Institutional Ethics Committee. IRB Nos.IRB00002640
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
* The abstract of this manuscript has been presented as part of a poster discussion at the Advanced Technologies and Treatment for Diabetes (ATTD), 2020, which was held from 19th – 22nd February 2020 in Madrid, Spain.
Data Availability
I take full responsibility for this data.
Abbreviations
- AI
- artificial intelligence
- Apps
- applications
- CVD
- cardiovascular disease
- MARS
- Mobile App Rating Scale
- mHealth
- mobile health
- T2D
- type 2 diabetes
